Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Expects Multiple Celexa Generics To Enter Market In January

This article was originally published in The Pink Sheet Daily

Executive Summary

Company sees "no impediments" to ANDA approvals for antidepressant, beyond demands on FDA resources to review multiple applications simultaneously. Forest believes the agency will try to approve all generics simultaneously, making it difficult to complete the reviews before the end of the year.

You may also be interested in...



Alphapharm's Attempt To Force Listing of Celexa Patent Rejected By Court

Federal judge affirms FDA's "ministerial" role in declining to list certain patents in the "Orange Book." Forest said the patent should not be listed because it claims an intermediate of citalopram.

Alphapharm's Attempt To Force Listing of Celexa Patent Rejected By Court

Federal judge affirms FDA's "ministerial" role in declining to list certain patents in the "Orange Book." Forest said the patent should not be listed because it claims an intermediate of citalopram.

Lexapro SSRI Switch Plan On Target Despite Slower Than Expected Decline In Celexa Sales

Forest attributes the majority of Celexa’s $15.4 mil. sequential quarterly sales growth to a 4% price increase taken in March. Forest’s estimates put the Celexa revenue run rate in early 2005 at $680 mil., above earlier predictions.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel